Recognition highlights GeneDx’s leadership in moving genomic medicine to the forefront of healthcare

GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity by Fierce Pharma, Fierce Biotech and Fierce Healthcare. The Fierce 50 recognizes 50 individuals and organizations driving advancements in medicine, fostering innovation and shaping the future of biopharma and healthcare.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901577181/en/

"What makes this recognition so meaningful is seeing genomics take its place in the broader healthcare conversation," said Stueland. "We know that when patients get the right diagnosis earlier, everything that follows can change. Genomic medicine has the power to fundamentally improve how care is delivered, and at GeneDx, we’re proving what’s possible when genomics becomes part of the standard of care."

Under Stueland’s leadership, GeneDx is making earlier, more accurate diagnosis a standard part of healthcare. By combining deep clinical expertise, advanced technology and GeneDx Infinity™, the world’s largest rare disease genomic dataset, the company is bringing genomic medicine into clinical care at scale to enable a more proactive, precise and efficient healthcare system.

"Now in its fourth year, the Fierce 50 continues to show that progress in this industry doesn’t come from just one place," said Ayla Ellison, editor-in-chief of Fierce Life Sciences and Healthcare. "It’s showing up in the lab, in executive leadership, in community clinics and in advocacy work that never makes headlines. Whether it’s a biotech pushing a new therapy toward patients or a grassroots organization fighting for someone to get the care they need, these honorees remind us that impact takes a lot of different shapes. We’re honored to celebrate all of them."

About GeneDx

GeneDx’s (NASDAQ:WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity^™ – the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx^™ and GenomeDx^® tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,000 research publications, GeneDx is building the network that will drive the future of genomic precision medicine. For more information, visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.

About Fierce Pharma

Fierce Pharma is the go-to destination for the news and trends shaping the industry. Our focus daily is on news about approved drugs and every aspect of pharma’s operations as well as the people who move pharma forward. Our coverage also feeds longer-form content, podcasts and events. In staying on top of the news, our journalists have developed a loyal audience. Critically, we explain the news—often complicated technology or business maneuvers—and put it in context that brings it home for our readers and listeners in their work lives.

About Fierce Biotech

Fierce Biotech is the dominant B2B news brand for the industry. Every day, we track the companies, people and ideas reshaping biotech: from the discovery through clinical trials, approvals and commercialization, and the venture funding, partnerships, IPOs and M&A that power it all. That reporting fuels our long-form features, podcasts and events, where deal flow, data and on-the-ground insight come together into the fullest picture of where the industry is headed.

About Fierce Healthcare

At Fierce Healthcare, we deliver the news and analysis that healthcare can't afford to miss. Our newsroom serves the people building, running, and reshaping this industry: hospital executives and physicians, payers, policymakers, researchers and the entrepreneurs betting on what comes next. Wherever healthcare is being disrupted, financed, regulated, or reinvented, we're covering it, with breaking news, exclusive interviews and deep reporting that connects the dots between a boardroom decision and a patient's bedside experience.

Forward Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business plans, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, and (iv) future expansion of insurance coverage for exome and genome testing. The foregoing list of factors is not exhaustive. A further list and description of risks, uncertainties and other matters can be found in the "Risk Factors" section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, filed with the SEC on May 4, 2026, our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026, filed with the SEC on August 3, 2026 and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260901577181/en/

Investor Relations:

Investors@GeneDx.com

Media:

Press@GeneDx.com